Copyright
©The Author(s) 2017.
World J Gastroenterol. Sep 14, 2017; 23(34): 6294-6305
Published online Sep 14, 2017. doi: 10.3748/wjg.v23.i34.6294
Published online Sep 14, 2017. doi: 10.3748/wjg.v23.i34.6294
Figure 1 Associations between availability, affordability, gross domestic product per capita and the uptake of biosimilars.
Cz: The Czech Republic; Fr: France; D: Germany; Hu: Hungary; Lv: Latvia; Pl: Poland; Ro: Romania; Sk: Slovakia; Es: Spain; Se: Sweden; Prevalence: Patients on biologicals per 100000 population. GDP: Gross domestic product.
- Citation: Péntek M, Lakatos PL, Oorsprong T, Gulácsi L, Pavlova M, Groot W, Rencz F, Brodszky V, Baji P, Crohn’s Disease Research Group. Access to biologicals in Crohn’s disease in ten European countries. World J Gastroenterol 2017; 23(34): 6294-6305
- URL: https://www.wjgnet.com/1007-9327/full/v23/i34/6294.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i34.6294